Developer docs
API playgroundTry for free, no card

Search company profiles

Stimwave Technologies

Full company profile

uuid0003dbw

Namestring
Stimwave Technologies
Legal namestring
Stimwave Technologies Incorporated
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Stimwave Technologies was a privately held U.S. medical device company founded in 2010 and headquartered in Pompano Beach, Florida, that developed and commercialized wireless, microsize injectable neuromodulation devices for chronic pain management. Its product portfolio centered on two FDA-cleared systems under the Freedom® brand: the Freedom® SCS spinal cord stimulator and the Freedom® PNS peripheral nerve stimulator, both designed to deliver electrical stimulation therapy without the bulk of conventional implanted pulse generators. The underlying technology differentiated Stimwave from incumbent wired IPG-based neuromodulation systems (sold by Medtronic, Boston Scientific, Abbott, and Nevro) by miniaturizing the implant to a wirelessly powered, injectable form factor intended for simpler implantation and improved patient comfort.

The company raised approximately $115 million in disclosed equity and convertible financing across multiple rounds between 2012 and 2020, with capital concentrated in two 2018 rounds ($50 million Series 3 and a $60 million round led by E Squared Capital Management, Generation Ventures, and SV Health Investors). Its go-to-market relied on physician-channel adoption among pain-management specialists, and the company maintained both U.S. and international Instructions-for-Use documentation, indicating at least some ex-U.S. distribution. Stimwave Technologies Incorporated and Stimwave LLC filed a voluntary Chapter 11 petition in the District of Delaware on June 15, 2022; certain assets were subsequently sold to Curonix LLC on October 31, 2022. Following the sale, the original Stimwave entities ceased independent operations, and Curonix assumed responsibility for supporting previously implanted Freedom® devices and continues to offer PNS and SCS devices under its own brand.

Short descriptiontext

Stimwave Technologies was a U.S. medical device company that developed wireless, microsize injectable neuromodulation systems — the Freedom PNS and Freedom SCS — for chronic pain patients. It filed Chapter 11 in 2022 and sold its assets to Curonix LLC, ceasing independent operations.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPompano Beach, United States
HQ citystring
Pompano Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neuromodulation devices, spinal cord stimulation, peripheral nerve stimulation, chronic pain management, implantable medical devices
Industry1 code
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Implantable Neuromodulation Devices
Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Freedom SCS
Description

Spinal cord stimulation device system

stimwavefreedom.com
+1 more record
Core offering1 text field

Stimwave Technologies developed and marketed wireless, microsize, injectable neuromodulation devices for chronic pain management. Its principal products were the Freedom SCS spinal cord stimulation system and the Freedom PNS peripheral nerve stimulation system, both delivering electrical stimulation therapy via fully implanted, leadless stimulators. The company ceased independent operations after a Chapter 11 filing in June 2022, with assets acquired by Curonix LLC in October 2022.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Stimwave Technologies offered a portfolio of neuromodulation devices for chronic pain management, specifically the Freedom® SCS (Spinal Cord Stimulation) and Freedom® PNS (Peripheral Nerve Stimulation) systems. These wireless, implantable neurostimulation devices provided electrical stimulation to treat chronic pain conditions. The company filed for Chapter 11 bankruptcy protection in June 2022 and certain assets were subsequently purchased by Curonix LLC in October 2022. The Freedom® product line is no longer manufactured under the Stimwave name, with Curonix continuing to provide support for previously implanted devices and offering currently available peripheral nerve and spinal cord stimulation devices.

Product and service1 record
1Freedom SCS
Partnership1 partner
Strategic tierMajorTypeOthersAnnounced on2022-10-31
Description

Curonix LLC purchased Stimwave assets following the bankruptcy sale on October 31, 2022. Curonix is providing ongoing support for previously implanted Stimwave devices (Freedom® PNS and Freedom® SCS) and is working with physicians to maintain patient care. Curonix now offers peripheral nerve and spinal cord stimulation devices under its own brand.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nevro is a direct competitor in spinal cord stimulation, offering the Senza and HFX platforms for chronic pain. Like Stimwave's Freedom SCS, Nevro targets interventional pain specialists and neurosurgeons with implantable neurostimulators.

TypeBroad incumbent
Description

Medtronic is the largest incumbent in neuromodulation, offering Intellis with Vanta for SCS and a broad PNS portfolio. It competes directly with Stimwave's Freedom SCS and Freedom PNS in the same physician call points.

3Abbott
TypeOthers
Description

Abbott (via St. Jude Medical) markets the Proclaim XR and Eterna SCS systems plus Proclaim DRG for neuropathic pain, directly overlapping Stimwave's Freedom SCS in chronic pain indications.

TypeBroad incumbent
Description

Boston Scientific offers the Precision Spectra, WaveWriter Alpha, and Montage MRI SCS systems, competing head-to-head with Freedom SCS in U.S. interventional pain practices.

TypeDirect peer
Description

Curonix acquired Stimwave's assets in October 2022 and now markets PNS and SCS devices under its own brand. It is effectively the commercial successor to Stimwave's Freedom product line.

TypeEmerging player
Description

Nalu Medical develops a miniaturized, externally-powered neurostimulator for PNS and SCS, conceptually similar to Stimwave's wireless micro-implant approach and targeting the same chronic pain use cases.

TypeEmerging player
Description

Saluda Medical markets the Evoke closed-loop SCS system and is developing a next-generation Evoke SmartSpine platform, competing directly with Freedom SCS in the chronic pain neuromodulation segment.

TypeEmerging player
Description

SPR Therapeutics focuses on peripheral nerve stimulation (the Sprint PNS system), a direct competitor to Stimwave's Freedom PNS in treating chronic and post-surgical pain.

TypeBroad incumbent
Description

Axonics is a neuromodulation company best known for sacral neuromodulation but expanding into SNS and other indications, sharing Stimwave's implantable neurostimulator category and physician customer base.

TypeEmerging player
Description

Mainstay Medical develops the ReActiv8 restorative neurostimulation system for chronic low back pain, overlapping with Stimwave's clinical positioning in neuromodulation for chronic pain.

Market position
Strengths2 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Stimwave Technologies

Implantable Neuromodulation Devicesstimwavefreedom.com

Stimwave Technologies was a U.S. medical device company that developed wireless, microsize injectable neuromodulation systems — the Freedom PNS and Freedom SCS — for chronic pain patients. It filed Chapter 11 in 2022 and sold its assets to Curonix LLC, ceasing independent operations.

What Stimwave Technologies does

Stimwave Technologies was a privately held U.S. medical device company founded in 2010 and headquartered in Pompano Beach, Florida, that developed and commercialized wireless, microsize injectable neuromodulation devices for chronic pain management. Its product portfolio centered on two FDA-cleared systems under the Freedom® brand: the Freedom® SCS spinal cord stimulator and the Freedom® PNS peripheral nerve stimulator, both designed to deliver electrical stimulation therapy without the bulk of conventional implanted pulse generators. The underlying technology differentiated Stimwave from incumbent wired IPG-based neuromodulation systems (sold by Medtronic, Boston Scientific, Abbott, and Nevro) by miniaturizing the implant to a wirelessly powered, injectable form factor intended for simpler implantation and improved patient comfort.

The company raised approximately $115 million in disclosed equity and convertible financing across multiple rounds between 2012 and 2020, with capital concentrated in two 2018 rounds ($50 million Series 3 and a $60 million round led by E Squared Capital Management, Generation Ventures, and SV Health Investors). Its go-to-market relied on physician-channel adoption among pain-management specialists, and the company maintained both U.S. and international Instructions-for-Use documentation, indicating at least some ex-U.S. distribution. Stimwave Technologies Incorporated and Stimwave LLC filed a voluntary Chapter 11 petition in the District of Delaware on June 15, 2022; certain assets were subsequently sold to Curonix LLC on October 31, 2022. Following the sale, the original Stimwave entities ceased independent operations, and Curonix assumed responsibility for supporting previously implanted Freedom® devices and continues to offer PNS and SCS devices under its own brand.

Stimwave Technologies firmographics

Firmographics
Name
Stimwave Technologies
Legal name
Stimwave Technologies Incorporated
Website
https://stimwavefreedom.com
Company type
Private
Founded year
2022
Operating status
Closed
Headcount range
51–100 employees
Short description
Stimwave Technologies was a U.S. medical device company that developed wireless, microsize injectable neuromodulation systems — the Freedom PNS and Freedom SCS — for chronic pain patients. It filed Chapter 11 in 2022 and sold its assets to Curonix LLC, ceasing independent operations.
Ownership category
akta.pro rank

Stimwave Technologies industry classification

Industry
Product category
Implantable Neuromodulation Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Neuromodulation devices
  • Spinal cord stimulation
  • Peripheral nerve stimulation
  • Chronic pain management
  • Implantable medical devices

Where Stimwave Technologies is headquartered

Location

Headquarters

HQ city
Pompano Beach
HQ country
United States
HQ region
North America

Markets served

Stimwave Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Stimwave Technologies product offering

Product offering

Core offering

Stimwave Technologies developed and marketed wireless, microsize, injectable neuromodulation devices for chronic pain management. Its principal products were the Freedom SCS spinal cord stimulation system and the Freedom PNS peripheral nerve stimulation system, both delivering electrical stimulation therapy via fully implanted, leadless stimulators. The company ceased independent operations after a Chapter 11 filing in June 2022, with assets acquired by Curonix LLC in October 2022.

Product overview

Stimwave Technologies offered a portfolio of neuromodulation devices for chronic pain management, specifically the Freedom® SCS (Spinal Cord Stimulation) and Freedom® PNS (Peripheral Nerve Stimulation) systems. These wireless, implantable neurostimulation devices provided electrical stimulation to treat chronic pain conditions. The company filed for Chapter 11 bankruptcy protection in June 2022 and certain assets were subsequently purchased by Curonix LLC in October 2022. The Freedom® product line is no longer manufactured under the Stimwave name, with Curonix continuing to provide support for previously implanted devices and offering currently available peripheral nerve and spinal cord stimulation devices.

Differentiator

Problem solved

Functional benefit

Brands

  • Freedom SCS: Spinal cord stimulation device system
  • Freedom PNS

Products and services

  • Freedom SCS

Companies that use Stimwave Technologies

Customer profile

Ideal customer profiles1 record

Stimwave Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Stimwave Technologies partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Curonix LLCmajorOthers · 31 October 2022Curonix LLC purchased Stimwave assets following the bankruptcy sale on October 31, 2022. Curonix is providing ongoing support for previously implanted Stimwave devices (Freedom® PNS and Freedom® SCS) and is working with physicians to maintain patient care. Curonix now offers peripheral nerve and spinal cord stimulation devices under its own brand.

Recent moves7 records

Expansion highlights2 records

Stimwave Technologies competitors and assessment

Company assessment

Direct peers

  • Nevro Corp: Nevro is a direct competitor in spinal cord stimulation, offering the Senza and HFX platforms for chronic pain. Like Stimwave's Freedom SCS, Nevro targets interventional pain specialists and neurosurgeons with implantable neurostimulators.
  • Curonix LLC: Curonix acquired Stimwave's assets in October 2022 and now markets PNS and SCS devices under its own brand. It is effectively the commercial successor to Stimwave's Freedom product line.

Broad incumbents

  • Medtronic: Medtronic is the largest incumbent in neuromodulation, offering Intellis with Vanta for SCS and a broad PNS portfolio. It competes directly with Stimwave's Freedom SCS and Freedom PNS in the same physician call points.
  • Boston Scientific: Boston Scientific offers the Precision Spectra, WaveWriter Alpha, and Montage MRI SCS systems, competing head-to-head with Freedom SCS in U.S. interventional pain practices.
  • Axonics: Axonics is a neuromodulation company best known for sacral neuromodulation but expanding into SNS and other indications, sharing Stimwave's implantable neurostimulator category and physician customer base.

Others

  • Abbott: Abbott (via St. Jude Medical) markets the Proclaim XR and Eterna SCS systems plus Proclaim DRG for neuropathic pain, directly overlapping Stimwave's Freedom SCS in chronic pain indications.

Emerging players

  • Nalu Medical: Nalu Medical develops a miniaturized, externally-powered neurostimulator for PNS and SCS, conceptually similar to Stimwave's wireless micro-implant approach and targeting the same chronic pain use cases.
  • Saluda Medical: Saluda Medical markets the Evoke closed-loop SCS system and is developing a next-generation Evoke SmartSpine platform, competing directly with Freedom SCS in the chronic pain neuromodulation segment.
  • SPR Therapeutics: SPR Therapeutics focuses on peripheral nerve stimulation (the Sprint PNS system), a direct competitor to Stimwave's Freedom PNS in treating chronic and post-surgical pain.
  • Mainstay Medical: Mainstay Medical develops the ReActiv8 restorative neurostimulation system for chronic low back pain, overlapping with Stimwave's clinical positioning in neuromodulation for chronic pain.

Market position

Strengths2 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Stimwave Technologies social profiles

Digital presence

Stimwave Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Stimwave Technologies leadership team

Management profile

Number of profiles

Stimwave Technologies funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Stimwave Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Stimwave Technologies

What does Stimwave Technologies do?

Stimwave Technologies developed and marketed wireless, microsize, injectable neuromodulation devices for chronic pain management. Its principal products were the Freedom SCS spinal cord stimulation system and the Freedom PNS peripheral nerve stimulation system, both delivering electrical stimulation therapy via fully implanted, leadless stimulators. The company ceased independent operations after a Chapter 11 filing in June 2022, with assets acquired by Curonix LLC in October 2022.

Is Stimwave Technologies a public or private company?

Stimwave Technologies is a private company. It is classified as venture growth investor backed and is currently closed.

When was Stimwave Technologies founded?

Stimwave Technologies was founded in 2022. It employs 51 to 100 people.

Where is Stimwave Technologies based?

Stimwave Technologies is headquartered in Pompano Beach, United States, in the North America region.

Who are Stimwave Technologies's main competitors?

Direct peers on record are Nevro Corp and Curonix LLC. Broad incumbents are Medtronic, Boston Scientific and Axonics. Abbott is listed as an others. Emerging players are Nalu Medical, Saluda Medical, SPR Therapeutics and Mainstay Medical.

Does Stimwave Technologies have an API?

No public API is recorded for Stimwave Technologies.

What industry is Stimwave Technologies in?

Stimwave Technologies's product category is Implantable Neuromodulation Devices. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Law360Del. Chancery Says Curonix Owns Stimwave SharesDelaware's Court of Chancery ruled that Curonix LLC, a medical device company, is the rightful owner of 75,000 shares of Stimwave Technologies Inc., which it purchased in bankruptcy. The court found Curonix to be the plaintiff in its lawsuit against Stimwave's founder.openPR.comPain Management Devices Market is Predicted to Achieve USD 6.3 by 2031, Growing at a CAGR of 7.1% Over the Forecast Period | Stim Wave LLC, Baxter International, Inc., Boston Scientific CorpThe global pain management devices market reached USD 3.7 billion in 2022 and is projected to grow to USD 6.3 billion by 2031, a CAGR of 7.1%. Key players include Stim Wave, Baxter, and Boston Scientific, with recent FDA approvals and product launches noted.openPR.comPain Management Devices Market to Witness Massive Growth (2024-2031)| Stim Wave LLC, Baxter International, Inc., Boston Scientific Corp., ICU Medical IncDataM Intelligence released a market research report on pain management devices, projecting the market to grow from USD 3.7 billion in 2022 to USD 6.3 billion by 2031, a CAGR of 7.1%. Key developments include Abbott's FDA approval of spinal cord stimulators for nonsurgical back pain and a partnership between Chugai and Biofourmis for endometriosis pain.STATFormer medical device CEO who sold fake plastic parts sentenced to 6 years in prisonLaura Perryman, former CEO of Stimwave, was sentenced to six years in prison for selling pain-relief devices with dummy plastic parts. The company sold nearly 8,000 devices from 2017 to 2020, allowing doctors to claim about $18,000 more per device.GlobeNewswireCuronix Celebrates 1st AnniversaryCuronix LLC celebrated its first anniversary on Nov. 1, 2023, after acquiring Stimwave Technologies in Nov. 2022. The company hired 75 new employees, trained over 500 healthcare professionals, and published six clinical studies on its Freedom PNS system. It also secured backing from Kennedy Lewis and Broadfin Holding.Business InsiderFake plastic medical devices were implanted into people with chronic pain. It was part of a medical company CEO's scheme to charge $16,000 for each one, feds allege.Laura Perryman, former CEO of Stimwave, was arrested and charged with healthcare fraud for selling fake plastic implants to doctors for $16,000 each. The devices had no medical efficacy, and she faces up to 30 years in prison. Stimwave agreed to pay $10 million in penalties.FierceBiotechDOJ charges former Stimwave CEO with fraud scheme that added a fake receiver to neurostim deviceLaura Perryman, former CEO of Stimwave, was arrested in Florida and charged with healthcare fraud and conspiracy to commit wire fraud and healthcare fraud. The scheme involved adding a fake plastic receiver to the StimQ neurostimulator, enabling insurers to reimburse $16,000–$18,000 per system instead of $4,000–$6,000. Stimwave settled a civil fraud lawsuit for $8.6 million, credited to a $10 million fine.Business Wire BlogStimwave Technologies and Aspen Medical Products Partner to Enhance Patient Satisfaction Through the Development of Wearable Pain Management SolutionsStimwave Technologies and Aspen Medical Products announced a collaboration to develop a wearable pain management accessory for Stimwave's Freedom Spinal Cord Stimulator patients. The wearable houses external components discreetly under clothing, combining Stimwave's wireless power technology with Aspen's design experience. Clinicians are invited to learn more at ASIPP 2022.BioSpaceStimwave Technologies Receives Reimbursement Authorization in GermanyStimwave Technologies received additional reimbursement authorization in Germany, with its Freedom PNS and SCS products granted NUB Status 1 designation. This allows hospitals to negotiate reimbursement with statutory health insurers. The company expects a material positive impact on patient access.BioSpaceStimwave Technologies Announces Chris Valois as Chief Marketing and Strategy OfficerStimwave Technologies appointed Chris Valois as Chief Marketing and Strategy Officer, a newly created role. Valois brings over two decades of medical technology leadership, including roles at FH Ortho, Xtant Medical, and Tornier. The company plans to accelerate commercialization of its spinal cord and peripheral nerve stimulation platforms.